ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Other Events
Item8.01
| Other Events. |
On March17, 2017, Zosano Pharma Corporation (the Company) filed
an Issuer Free Writing Prospectus relating to the Companys
Preliminary Prospectus dated March13, 2017 (Registration
No.333-216410). A copy of the Issuer Free Writing Prospectus is
attached hereto as Exhibit 99.1 and incorporated herein by
reference.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
Exhibit Number |
Exhibit Description |
|
| 99.1 |
Issuer Free Writing Prospectus dated March17, 2017 filed to Rule 433 relating to the Companys Preliminary Prospectus dated March13, 2017 (Registration No.333-216410). |
2
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| ZOSANO PHARMA CORPORATION | ||||||||
| Dated:March 17, 2017 | By: |
/s/ Georgia Erbez |
||||||
| Name: | Georgia Erbez | |||||||
| Title: | Chief Business Officer and Interim Chief Financial Officer |
3
EXHIBIT INDEX
|
Exhibit Number |
ExhibitDescription |
|
| 99.1 | Issuer Free Writing Prospectus dated March17, 2017 filed |
About ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN)
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon. ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Recent Trading Information
ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) closed its last trading session down -0.15 at 1.57 with 5,067,729 shares trading hands.
